Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;91(3):364-71.
doi: 10.1016/j.pec.2012.12.014. Epub 2013 Feb 8.

Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer

Matthew P Banegas  1 , Jennifer B McClure, William E Barlow, Peter A Ubel, Dylan M Smith, Brian J Zikmund-Fisher, Sarah M Greene, Angela Fagerlin
Affiliations
Randomized Controlled Trial

Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer

Matthew P Banegas et al. Patient Educ Couns. 2013 Jun.

Abstract

Objective: To assess the impact of Guide to Decide (GtD), a web-based, personally-tailored decision aid designed to inform women's decisions about prophylactic tamoxifen and raloxifene use.

Methods: Postmenopausal women, age 46-74, with BCRAT 5-year risk ≥ 1.66% and no prior history of breast cancer were randomized to one of three study arms:intervention (n=690), Time 1 control (n=160), or 3-month control (n=162). Intervention participants viewed GtD prior to completing a post-test and 3 month follow-up assessment. Controls did not. We assessed the impact of GtD on women's decisional conflict levels and treatment decision behavior at post-test and at 3 months, respectively.

Results: Intervention participants had significantly lower decisional conflict levels at post-test (p<0.001) and significantly higher odds of making a decision about whether or not to take prophylactic tamoxifen or raloxifene at 3-month follow-up (p<0.001) compared to control participants.

Conclusion: GtD lowered decisional conflict and helped women at high risk of breast cancer decide whether to take prophylactic tamoxifen or raloxifene to reduce their cancer risk.

Practice implications: Web-based, tailored decision aids should be used more routinely to facilitate informed medical decisions, reduce patients' decisional conflict, and empower patients to choose the treatment strategy that best reflects their own values.

Trial registration: ClinicalTrials.gov NCT00967824.

PubMed Disclaimer

Conflict of interest statement

Competing interests

None declared.

Figures

Fig. 1
Fig. 1
Guide to Decide consort diagram.
Fig. 2
Fig. 2
Participants’ stage of decision making at 3-month follow-up. Notes: Percentages based on those participants who reported to have not made a decision about whether or not to take a chemoprevention drug at 3-month follow up (intervention group n = 171, Time 1 control n = 67, and 3-month control n = 70).
Fig. 3
Fig. 3
Stage of decision making and preparation for decision making among intervention group participants in the decision making process. Notes: The F-statistic is based on the F-test for trend. Estimated values are the mean preparation for decision making (PrepDM) score, at post-test, among intervention group participants in each stage of the decision making process, who had not made a decision about whether or not to take a breast cancer chemoprevention drug at 3-month follow-up survey. All responses are based on intervention group participants with a valid (non-missing) post-test PrepDM score (n = 169).
See this image and copyright information in PMC

References

    1. Graubard BI, Freedman AN, Gail MH. Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening. Cancer Epidemiol Biomarkers Prev. 2010;19:2430–6. - PMC - PubMed
    1. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8. - PubMed
    1. Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol. 2003;21:593–601. - PubMed
    1. Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8:1112–46. - PubMed
    1. Visvanathan K, Lippman SM, Hurley P, Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol. 2009;115:132–4. - PMC - PubMed

Publication types

Associated data